Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on February 20, 2024, the publication of new data in the International Journal of Molecular Sciences demonstrating that its investigational drug opaganib significantly improves long-term survival in a mouse model of lung damage following ionizing radiation exposure. The study indicates opaganib's potential as a medical countermeasure against radiation-induced lung inflammation and fibrosis. Opaganib, a selective sphingosine kinase-2 (SPHK2) inhibitor, is being developed for multiple indications, including Acute Radiation Syndrome (ARS), COVID-19, and oncology. The U.S. National Institutes of Health's Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for its Product Development Program. The drug, which is easy to administer and has a five-year shelf-life, could be stockpiled by governments for use in radiological or nuclear incidents, pending FDA approval. The publication also highlights opaganib's potential benefits in cancer radiotherapy and its host-directed mechanism, which may maintain efficacy against emerging viral variants.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on February 20, 2024, the publication of new data in the International Journal of Molecular Sciences demonstrating that its investigational drug opaganib significantly improves long-term survival in a mouse model of lung damage following ionizing radiation exposure. The study indicates opaganib's potential as a medical countermeasure against radiation-induced lung inflammation and fibrosis. Opaganib, a selective sphingosine kinase-2 (SPHK2) inhibitor, is being developed for multiple indications, including Acute Radiation Syndrome (ARS), COVID-19, and oncology. The U.S. National Institutes of Health's Radiation and Nuclear Countermeasures Program (RNCP) has selected opaganib for its Product Development Program. The drug, which is easy to administer and has a five-year shelf-life, could be stockpiled by governments for use in radiological or nuclear incidents, pending FDA approval. The publication also highlights opaganib's potential benefits in cancer radiotherapy and its host-directed mechanism, which may maintain efficacy against emerging viral variants.
专业生物制药公司RedHill Biopharma Ltd. 于2024年2月20日宣布，在《国际分子科学杂志》上发布新数据，表明其研究药物奥帕加尼布显著改善了电离辐射暴露后肺损伤小鼠模型的长期存活率。该研究表明，奥帕加尼布有可能作为一种针对辐射引起的肺部炎症和纤维化的医学对策。奥帕加尼布是一种选择性鞘氨醇激酶-2（SPHK2）抑制剂，正在开发用于多种适应症，包括急性辐射综合症（ARS）、COVID-19 和肿瘤学。美国国立卫生研究院的辐射与核对策计划（RNCP）已选择奥帕加尼布作为其产品开发计划。这种药物易于使用，保质期为五年，在等待美国食品药品管理局批准之前，政府可以储存用于放射性或核事故。该出版物还重点介绍了奥帕加尼布在癌症放射治疗中的潜在益处及其宿主导机制，该机制可能会保持对新出现的病毒变异的疗效。
专业生物制药公司RedHill Biopharma Ltd. 于2024年2月20日宣布，在《国际分子科学杂志》上发布新数据，表明其研究药物奥帕加尼布显著改善了电离辐射暴露后肺损伤小鼠模型的长期存活率。该研究表明，奥帕加尼布有可能作为一种针对辐射引起的肺部炎症和纤维化的医学对策。奥帕加尼布是一种选择性鞘氨醇激酶-2（SPHK2）抑制剂，正在开发用于多种适应症，包括急性辐射综合症（ARS）、COVID-19 和肿瘤学。美国国立卫生研究院的辐射与核对策计划（RNCP）已选择奥帕加尼布作为其产品开发计划。这种药物易于使用，保质期为五年，在等待美国食品药品管理局批准之前，政府可以储存用于放射性或核事故。该出版物还重点介绍了奥帕加尼布在癌症放射治疗中的潜在益处及其宿主导机制，该机制可能会保持对新出现的病毒变异的疗效。
有用
没用